肝动脉化疗栓塞术联合中药肝癌Ⅰ、Ⅱ号治疗中晚期肝癌的临床观察

目的：观察肝动脉化疗栓塞术（HACE）联合中药肝癌Ⅰ、Ⅱ号治疗中、晚期肝癌的临床疗效。方法：中、晚期肝癌患者60例，随机分为两组，A组30例，应用HACE联合中药肝癌Ⅰ号（口服）、Ⅱ号（外敷）56．7％、30．0％，B组分别为50．0％、33．3％、16．7％。1、2年复发率A组分别为43．3％、66．7％，B组分别为66．7％、90．0％。肿瘤缩小、甲球蛋白降低、外周血WBC下降程度A组均明显优于B组（P＜0．01）。在临床症状改善方面A组患者比B组患者更明显。结论：本法对中、晚期肝癌疗效明显。

Clinical Study onTreatment of Middle-Advanced Stage Liver Cancer by Combined Treatment of Hepatic ArteryChemoembolization with Gan

OBJECTIVE: To observe the clinical effect of combined treatment of hepatic artery chemoembolization (HACE) and Chinese herbal medicine (CHM) in treating middle-advanced stage liver cancer. METHODS: Sixty patients with middle-advanced stage liver cancer were randomly divided into two groups. The 30 patients in Group A were treated with combined HACE and Chinese herbal medicine (Gan'ai No. I and No. II) and the other 30 in Group B were treated with HACE alone. All patients were followed up for over 3 years. RESULTS: The 0.5-, 1- and 2-year survival rate in Group A was 76.7%, 56.7% and 30.0% respectively, and those in Group B was 50.0%, 33.3% and 16.7% respectively. The 1- and 2-year recurrence rate in Group A was 43.3%, 66.7% and that in Group B was 66.7%, 90.0% respectively. Moreover, Group A was significantly superior to Group B in tumor shrinking, AFP decreasing and blood leucocyte reducing (P < 0.01), as well as in improving clinical symptoms. CONCLUSION: The combined treatment has obvious effect in treating middle-advanced stage liver cancer.